Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials.

•People of different racial/ethnic backgrounds have different lipid/risk profiles.•We assessed effects of alirocumab in subgroups by race/ethnicity from 3 trials.•Baseline factors, such as lipoprotein(a), differed among people of different race/ethnicity.•Overall significant reductions in low-density lipoprotein cholesterol were observed across race/ethnicity groups.•Adverse events similar to control and consistent across race/ethnicity groups.